Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 17 February 1984:
Vol. 223. no. 4637, pp. 698 - 701
DOI: 10.1126/science.6695178
Prev | Table of Contents | Next

Articles

Science, Vol 223, Issue 4637, 698-701
Copyright © 1984 by American Association for the Advancement of Science

articles

Somatic activation of rasK gene in a human ovarian carcinoma

LA Feig, RC Bast Jr, RC Knapp, and GM Cooper

A tumor isolate from a patient with serous cystadenocarcinoma of the ovary contained an activated rasK gene detected hy transfection of NIH/3T3 cells. In contrast, DNA from normal cells of the same patient lacked transforming activity, indicating that activation of this transforming gene was the consequence of somatic mutation in the neoplastic cells. The transforming gene product displayed an electrophoretic mobility in sodium dodecyl sulfate-polyacrylamide gels that differed from the mobilities of rasK transforming proteins in other tumors, indicating that a previously undescribed mutation was responsible for activation of rasK in this ovarian carcinoma.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Pathogenesis of Ovarian Cancers.
A. Berchuck, A. Elbendary, L. Havrilesky, G. C. Rodriguez, and R. C. Bast (1994)
Reproductive Sciences 1, 181-190
   Abstract »    PDF »
Ovarian Cancer: New Therapeutic Concepts, Renewed Optimism.
F. M. MUGGIA, M. J. PICCART, and J. L. SPEYER (1985)
Ann Intern Med 103, 795-797
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)